Clinical Trials | A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

The University of Virginia seeks adult women with newly diagnosed advanced cervical cancer with or without lymph node involvement for a clinical trial. The goal of this study is to test whether giving immunotherapy and chemotherapy before the combination of chemotherapy, radiation, and immunotherapy can better prevent cervical cancer from growing or coming back, compared to giving the usual treatment alone. If you decide to participate in this study, you may be randomized (assigned by chance) to one of two arms: • Arm I: Standard of Care treatment -- you will receive the standard treatment for your cancer • Arm II: Experimental Arm: Induction chemotherapy added to standard treatment of your cancer. You will receive chemotherapy with IV carboplatin and IV paclitaxel weekly for 6 weeks with the addition of IV pembrolizumab every 3 weeks for 2 cycles. That will be followed by the standard treatment of your cancer. This study involves blood draws, physical examinations, and tumor imaging examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT07061977